News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Procognia Limited Awarded 2005 Frost & Sullivan Competitive Strategy Leadership Award For Success In Providing Innovative Protein Array Technologies


10/19/2005 5:12:41 PM

MAIDENHEAD, England, September 22 /PRNewswire/ -- Procognia, a leader in cutting edge proteomic technologies, announces that they have been awarded the 2005 Frost & Sullivan Competitive Strategy Leadership Award for their expanding portfolio of protein array based technologies. Procognia is helping to develop a fuller understanding of proteins as targets and as therapeutics and is currently working on a programme to array the human proteome in druggable classes. Utilising technologies based around protein arrays, Procognia provides both the means for unravelling disease mechanisms and the discovery and development of drugs to treat those diseases.

Frost & Sullivan believes that Procognia has achieved outstanding and unparalleled success with these enabling protein array technologies and that the company is setting unprecedented trends for drug discovery research. Procognia's success is based on its expertise in protein arrays that translates into its core technologies for drug screening and glycosylation analysis. Procognia's protein arrays for drug screening are available either as catalogue themed arrays of functional human proteins exclusively via Sigma Aldrich, or directly from Procognia on a custom design basis. Whatever the customer requirement, Procognia's proprietary tag technology ensures their protein function arrays increase their productivity by delivering fast and reproducible results.

Correct glycosylation is critical in the development of protein-based biopharmaceuticals and monitoring early in process development can increase the likelihood of the success of a drug in subsequent clinical trials. Procognia's custom U-c Fingerprint technology removes the need for sample preparation and gives quantitative data in less than 4 hours, enabling near real-time glycosylation monitoring. Researchers wishing to look at glycosylation patterns in a wide range of proteins will have access to this technology via a kit-based product supplied exclusively under license by QIAGEN.

Frost & Sullivan Analyst, Charanya Ramachandran, said, "One of biggest factors contributing to our decision to give Procognia this award was our recognition that several leading life science suppliers - namely Sigma-Aldrich, QIAGEN and Perkin Elmer - had endorsed the value of this company's technologies by committing to marketing agreements and partnerships. Scientists in life science research, drug discovery and the industrial biopharmaceutical industry stand to benefit now that these products are commercially available."

Ron Long (CEO), Chris Lyddon (CFO) and Rachel Fallon (VP R&D and Operations) were present to receive Procognia's award at the Excellence in Healthcare Award Banquet on September 21st.

About Procognia:

Procognia Ltd, a 2004 World Economic Forum Technology Pioneer award winner, is focused on developing and commercialising its cutting edge proprietary technologies to enable the unravelling of disease mechanisms and the discovery and development of drugs to treat those diseases. In addition to developing its glycoanalysis technology, Procognia has developed arrays of biologically related proteins that retain their physiological function in the array format. Procognia was formed in April 2002 with a corporate headquarters and manufacturing in Maidenhead, United Kingdom. Commercial operations are run from the United Kingdom and Exton, PA, United States, and supported by R&D facilities in Maidenhead, United Kingdom and Ashdod, Israel. Further information available at www.procognia.com.

About Frost & Sullivan:

Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company's industry expertise integrates growth consulting, growth partnership services and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies and the investment community by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics and demographics. For more information, visit http://www.frost.com.

Contacts: Sue Cotrel VP Marketing, Procognia Ltd, +44-1628-513503, e-mail: sue.cotrel@procognia.com Media Contact: Katja Feick Corporate Communications Frost & Sullivan Phone: +49-69-77033-12 Fax: +49-69-234566 E-Mail: katja.feick@frost.com

Frost & Sullivan

CONTACT: Sue Cotrel, VP Marketing, Procognia Ltd, +44-1628-513503, e-mail:sue.cotrel@procognia.com. Media Contact: Katja Feick, CorporateCommunications, Frost & Sullivan, Phone: +49-69-77033-12, Fax:+49-69-234566, E-Mail: katja.feick@frost.com


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES